These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22695529)

  • 1. Atherosclerosis severity but not undiagnosed diabetes predicts new cardiovascular events of subjects in secondary cardiovascular prevention.
    Rizza S; Copetti M; Cardellini M; Porzio O; Luzi A; Pecchioli C; Martelli E; Valentini A; Ippoliti A; Romeo F; Pellegrini F; Lauro D; Lauro R; Federici M
    Atherosclerosis; 2012 Aug; 223(2):448-53. PubMed ID: 22695529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Effects of Fasting Glucose, Hemoglobin A
    Su WY; Chen SC; Huang YT; Huang JC; Wu PY; Hsu WH; Lee MY
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.
    Boden WE; Miller MG; McBride R; Harvey C; Snabes MC; Schmidt J; McGovern ME; Fleg JL; Desvigne-Nickens P; Anderson T; Kashyap M; Probstfield JL
    Am Heart J; 2020 Jun; 224():65-76. PubMed ID: 32335402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis.
    Vazquez-Benitez G; Desai JR; Xu S; Goodrich GK; Schroeder EB; Nichols GA; Segal J; Butler MG; Karter AJ; Steiner JF; Newton KM; Morales LS; Pathak RD; Thomas A; Reynolds K; Kirchner HL; Waitzfelder B; Elston Lafata J; Adibhatla R; Xu Z; O'Connor PJ
    Diabetes Care; 2015 May; 38(5):905-12. PubMed ID: 25710922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study.
    Anand SS; Dagenais GR; Mohan V; Diaz R; Probstfield J; Freeman R; Shaw J; Lanas F; Avezum A; Budaj A; Jung H; Desai D; Bosch J; Yusuf S; Gerstein HC;
    Eur J Prev Cardiol; 2012 Aug; 19(4):755-64. PubMed ID: 21551215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus.
    Fu L; Zhou Y; Sun J; Zhu Z; Xing Z; Zhou S; Wang Y; Tai S
    Cardiovasc Diabetol; 2021 Oct; 20(1):201. PubMed ID: 34610830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
    Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
    J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis.
    Rizza S; Copetti M; Cardellini M; Menghini R; Pecchioli C; Luzi A; Di Cola G; Porzio O; Ippoliti A; Romeo F; Pellegrini F; Federici M
    Atherosclerosis; 2015 Apr; 239(2):459-64. PubMed ID: 25687272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
    Inzucchi SE; Khunti K; Fitchett DH; Wanner C; Mattheus M; George JT; Ofstad AP; Zinman B
    J Clin Endocrinol Metab; 2020 Sep; 105(9):3025-35. PubMed ID: 32485734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
    Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
    Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study.
    Sasso FC; Lascar N; Ascione A; Carbonara O; De Nicola L; Minutolo R; Salvatore T; Rizzo MR; Cirillo P; Paolisso G; Marfella R;
    Cardiovasc Diabetol; 2016 Oct; 15(1):147. PubMed ID: 27733159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy.
    Roumeliotis AK; Roumeliotis SK; Panagoutsos SA; Tsetsos F; Georgitsi M; Manolopoulos V; Paschou P; Passadakis PS
    Int Urol Nephrol; 2018 Feb; 50(2):321-329. PubMed ID: 29196930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in type-2 diabetes mellitus.
    Li WP; Neradilek MB; Gu FS; Isquith DA; Sun ZJ; Wu X; Li HW; Zhao XQ
    Cardiovasc Diabetol; 2017 Apr; 16(1):45. PubMed ID: 28381225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose.
    Lin CC; Chen CC; Chen FN; Li CI; Liu CS; Lin WY; Yang SY; Lee CC; Li TC
    Am J Med; 2013 Nov; 126(11):1017.e1-10. PubMed ID: 23993260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of cardiovascular disease and its associated risk factors in at-risk men and women in the United Arab Emirates: a 9-year retrospective cohort study.
    Al-Shamsi S; Regmi D; Govender RD
    BMC Cardiovasc Disord; 2019 Jun; 19(1):148. PubMed ID: 31208354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
    JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin, type 2 diabetes and cardiovascular risk.
    Lindberg S; Jensen JS; Bjerre M; Pedersen SH; Frystyk J; Flyvbjerg A; Galatius S; Jeppesen J; Mogelvang R
    Eur J Prev Cardiol; 2015 Mar; 22(3):276-83. PubMed ID: 24265290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.
    Ratner R; Han J; Nicewarner D; Yushmanova I; Hoogwerf BJ; Shen L
    Cardiovasc Diabetol; 2011 Mar; 10():22. PubMed ID: 21410975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial.
    Kumar A; Patel DR; Wolski KE; Lincoff AM; Kashyap SR; Ruotolo G; McErlean E; Weerakkody G; Riesmeyer JS; Nicholls SJ; Nissen SE; Menon V
    Diab Vasc Dis Res; 2019 Mar; 16(2):171-177. PubMed ID: 31014095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.